Paul Bassett holds a Bachelor’s and a Master’s degree in Analytical Chemistry from Youngstown State University and a BSN degree from Kent State University. Mr Bassett has over 25 years of pharmaceutical drug development and clinical research experience, leading research teams to develop formulations for Zithromax, Caduet, Zyrtec, Zoloft, and anti cancer drugs such as Fludara, Doxorubicin, Daunorubicin, Cisplatin, and Methotrexate.

Currently, Mr Bassett is a Project Lead in Early Development Oncology Operations at Sanofi. His mission has been to create new ways of working through the complexities of operationalizing pre-candidate molecules for FIH studies, through study start-up and conduct processes.

Liz Beatty is a co-founder and chief strategy officer at Inato, a clinical trials platform which flips the traditional model and allows community sites to participate in the trials that are best aligned with their interests and that of their patients. Ms Beatty is focused on advancing Inato’s corporate strategy, developing partnerships and driving growth in North America. Previously, she headed digital clinical trials at Bristol-Myers Squibb, where she led digital innovation efforts across global clinical operations.

Sanjay Bharwaj is the Global Head of Clinical Technology Strategy & Operations at AbbVie where he leads an organization of technologists who enable AbbVie’s clinical trials data collection, data processing, and deliver submission-ready datasets. Prior to AbbVie, Mr Bharwaj was the Global Head of Clinical Data Management at Allergan. For over more than 2 decades in the Clinical Operations – Clinical Data and Technology domain, he has led global teams at several bio-pharma companies such as Biogen, Novartis, and Merck. He is active in industry conferences and forums focused on clinical data. As chair of the board at the Society for Clinical Data Management, he led the organization through its most challenging times during the COVID-19 pandemic. Mr Bharwaj has authored a number of clinical data related publications.

Jordan Brayanov, PhD is a Head of Digital Strategy within the Data Sciences Institute at Takeda. In this role, Dr Brayanov oversees the strategic development and deployment of Digital Health Solutions and oversees the design and implementation of Decentralized Clinical Trials within clinical programs across the Takeda R&D organization.

Prior to joining Takeda, Dr Brayanov served as Vice President of Research at Respiratory Motion — a leader in respiratory volume monitoring. Dr Brayanov’s experience and research focus are on the design, development, and deployment of patient-centric tools and measurement equipment, advanced data modeling, and data visualization. Dr Brayanov holds a PhD in Computational Neuroscience from Harvard University.

Xuemei Cai oversees a clinical group within Worldwide Research, Development & Medical at Pfizer focused on developing and qualifying digital endpoints in clinical trials. Dr Cai also provides medical, scientific, and compliance oversight for the Pfizer Innovation Research Laboratory, an industry-leading, state-of-the-art research facility located in Cambridge, MA providing groundwork that enables the analytical and clinical validation of technology prior or in parallel to deployment in interventional clinical trials.

Dr Cai is a founding member of the Digital Medicine Society. She received her MD from Harvard Medical School. She remains a practicing ICU physician and has taken her passion for multimodal monitoring and improving functional prognostication and measurement tools for patients, families, and providers into the digital medicine space to improve the clinical trial experience for participants and enable new therapies.

Taras is Executive Director, Innovation and Process Improvement within Global Development Operations at Amgen. His team leads efforts to transform how clinical trials are conducted at Amgen, with a focus on cycle time reduction and reducing barriers to participation for patients and investigators. Prior to his current role, Mr Carpiac served in leadership positions at Amgen within Study Operations and Data Management. He holds a BA in History from University of California, Berkeley, and an MBA from Golden Gate University.

Jennifer Levin Carter is a Venture Partner at Sandbox Healthcare and the Blue Venture Fund. Dr Carter currently serves on the Board and/or as a strategic advisor to multiple public and private precision medicine, healthcare services, digital health and life science companies. She is also Founder and CEO of a Precision Medicine company in stealth.

Prior to Sandbox, Dr Carter served as a Managing Director of JLC Precision Health Strategies, LLC and in 2018, she founded TrialzOWN™, Inc., a healthcare company in stealth, and was CEO until its prelaunch acquisition by the Flagship Pioneering company, Integral Health, (now Valo Health), in 2019. Prior to TrialzOWN™, she was the Founder and President of N-of-One®, Inc, serving as acting-CEO from 2008-2012, and Chief Medical Officer from 2012 until its acquisition by Qiagen (Market Cap $8B) in 2019.

Dr Carter holds a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health, and an MBA from the Sloan School at Massachusetts Institute of Technology.

Janice Chang is the Chief Executive Officer at TransCelerate BioPharma Inc. Ms Chang has been involved with the organization since its inception. As CEO, she works closely with the Board of Directors to shape the long-term strategic vision and priorities for the organization and its 30+ initiatives. Ms Chang defines and guides TransCelerate’s overall external engagement strategy with global health authorities, governmental agencies, industry groups, and TransCelerate’s country network spanning across 30 countries. She has accountability overseeing TransCelerate’s corporate operations and works closely with her team to drive strategic delivery of TransCelerate’s portfolio. She also actively participates in various cross-stakeholder global discussions to help evolve the R&D paradigm.

With a background of 20+ years of experience leading initiatives in large pharma and biotech companies, Ms Chang has experience spanning across regulatory, clinical, and manufacturing.  Janice is passionate in driving meaningful change across our ecosystem and not settling for the status quo.  She believes in reimagining the way we advance innovative medicine and advocates for the power of open collaboration across stakeholder groups.

Andrew Pearlmutter is an Associate Director of Patient Centered Outcomes Science at BioMarin, with over 6 years of experience in patient-centered outcome (PCO) measurement design and implementation, with a focus on supporting digital health technology development and integration in clinical trials. Before joining BioMarin, Mr Pearlmutter was a Digital Biomarkers Consultant at Koneksa Health, a leading digital biomarker solutions provider. Mr Pearlmutter was also an inaugural member of Sanofi’s Digital Innovation team, where he led Sanofi’s efforts to build, test, and scale app- and wearable-based digital endpoints and health technologies in Parkinson’s Disease, Multiple Sclerosis, and rare diseases – including driving concept elicitation, regulatory engagements and clinical validation.

Greg Christie is a renowned thought leader in human-centered product development and design. As the Chief Product Officer at StudyKIK, he has gained recognition for his contributions to clinical research technology. Mr Christie’s work on the oncology app concept earned StudyKIK the SCOPE Participant Engagement Award, emphasizing his commitment to a collaborative and user-focused approach that prioritizes participant experience in cell and gene therapy trials.

Under Mr Christie’s leadership, StudyKIK was selected as a finalist for the esteemed Prix Galien UK 2023 Award in the ‘Best Digital Health Solution’ category. This distinction celebrates the patient-centric design and transformative impact of StudyKIK’s study companion applications across various therapeutic areas, including immunology and women’s health.

Mr Christie recently received the prestigious 2023 PM360 ELITE 100 Award in the Tech-Know Geek category for his contributions in reshaping the medtech landscape through innovative and patient-centric products.

Guiding StudyKIK’s Product and Design teams, Mr Christie brings a wealth of experience from his previous roles at technology organizations such as Goldstar Events, Evite, and prominent publications including Elle, Woman’s Day, Car and Driver, Road & Track, and Popular Photography. His expertise spans product development, design, branding, and marketing, positioning him as a versatile and influential leader in the field.

Eileen Doherty is the Head of Enabling Business Information Solutions (EBIS) team within Janssen R&D Global Development. The EBIS team enables the right technology solutions in clinical trials. Ms Doherty specializes in simplifying the “user experience” for their stakeholders, including clinical trial participants, sites, and internal study team members from clinical operations and R&D. Through advancements implemented by the EBIS team such as Telemedicine and ePRO (Patient Reported Outcome), clinical trial participants can reduce their travel to clinical trial sites and work through extensive paper questionnaire. As a proven and trusted leader, Ms Doherty, believes the most important customers are their clinical trial participants and sites.

Ms Doherty joined J&J from UCB Biosciences in 2018. During her 17 years at UCB, Ms Doherty’s experience included leading teams covering clinical data management, standards and programming, risk-based monitoring, reporting and analytics, SUSAR/safety reporting, as well as clinical trial systems. Earlier in her career, she worked in technology consulting, and had roles in both Clinical and Statistical Programming at a large contract research organization (CRO.) Ms Doherty holds a bachelor’s degree in Latin American Studies and Mathematics from the University of North Carolina at Chapel Hill.

Emma Eikermann is a product manager at Mural Health. In this capacity, among other responsibilities, Emma is responsible for steering long-term product strategy, designing and implementing new product features, and optimizing existing features to best service participants, sites, sponsors, and CROs. Prior to Mural Health, Ms Eikermann was a project manager for a custom app development group who worked extensively with clinical researchers to create new apps for their patients. Ms Eikermann’s past experience also includes direct experience as a site coordinator working in Phase 2 and Phase 3 trials at two major academic centers. Additionally, taking part in type 1 diabetes research, Ms Eikermann has also been on the participant side of clinical research.